Pre-Eclampsia
Conditions
Brief summary
The purpose of this research is to investigate the impact of hydroxychloroquine on the incidence of hypertensive pregnancy disorders in women with a history of recurrent spontaneous abortion (RSA).
Detailed description
Preeclampsia affects about 3-5% of all pregnancies and is estimated to cause at least 42 000 maternal deaths annually, remaining an important cause of death and complications for the mother and baby. However, no treatment yet has been found that affects disease progression except for termination of pregnancy which may cause iatrogenic preterm labor. Therefore, keenly sought for approaches to improving clinical outcomes in pre-eclampsia would be needed. Hydroxychloroquine (HCQ), an antimalarial drug, is commonly used in the treatment of pregnant women with RSA and has proven to be safe for both the mother and the fetus. Because of the antioxidant effect, anti-inflammatory effect, and vasculoprotective effect of HCQ, it has been thought to be beneficial in the prevention of preeclampsia. Therefore, we conducted a retrospective cohort study to evaluate the impact of HCQ treatment on the prevention of preeclampsia in RSA pregnancies.
Interventions
DRUGHydroxychloroquine
Hydroxychloroquine was administered during pregnancy
Sponsors
RenJi Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
1. singleton pregnant women 2. with a history of two or more miscarriages
Exclusion criteria
1. indication to a treatment according to the severe cardiovascular, immune, respiratory, gastrointestinal/liver and biliary system, kidney and urinary system, nervous system, musculoskeletal system, psychiatric, infectious disease, malignancy, 2. major malformation of the fetus diagnosed at 11-13 weeks of gestation. 3. Known paternal, maternal, or embryo chromosome abnormality; 4. Abnormal uterine anatomy at hysterosalpingography/hysteroscopy or hydrosonography that might explain RM in the first trimester of pregnancy; 5. Maternal endocrine dysfunction: premature ovarian failure, hyperprolactinemia, corpus luteal insufficiency, untreated diabetes mellitus or untreated thyroid dysfunction.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite morbidity | Gestational period | Preeclampsia, gestational hypertension, preeclampsia superimposed upon chronic hypertension |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| fetal growth restriction | 37 weeks of gestational age | \<10th percentile for gestational age |
| Preterm delivery | 37 weeks of gestational age | Delivery before 37 weeks |
| Abruptio placenta | 37 weeks of gestational age | The number of cases of abruptio placenta that appear in both groups at any given time during pregnancy |
Countries
China
Outcome results
None listed